Avadel Pharmaceuticals (AVDL) Competitors $8.03 -0.12 (-1.47%) Closing price 04:00 PM EasternExtended Trading$8.16 +0.13 (+1.67%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVDL vs. MRUS, ALVO, APLS, SRRK, CRNX, IMVT, ACAD, VKTX, XENE, and IBRXShould you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Avadel Pharmaceuticals vs. Merus Alvotech Apellis Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Immunovant ACADIA Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals ImmunityBio Merus (NASDAQ:MRUS) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Is MRUS or AVDL more profitable? Avadel Pharmaceuticals has a net margin of -52.53% compared to Merus' net margin of -680.61%. Merus' return on equity of -38.89% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Merus-680.61% -38.89% -31.16% Avadel Pharmaceuticals -52.53%-93.34%-44.77% Do insiders & institutionals have more ownership in MRUS or AVDL? 96.1% of Merus shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 4.6% of Merus shares are owned by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to MRUS or AVDL? In the previous week, Avadel Pharmaceuticals had 8 more articles in the media than Merus. MarketBeat recorded 14 mentions for Avadel Pharmaceuticals and 6 mentions for Merus. Merus' average media sentiment score of 0.98 beat Avadel Pharmaceuticals' score of 0.92 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, MRUS or AVDL? Merus has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$36.13M80.14-$154.94M-$3.27-12.82Avadel Pharmaceuticals$169.12M4.66-$160.28M-$0.52-15.67 Does the MarketBeat Community believe in MRUS or AVDL? Merus received 13 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 67.72% of users gave Merus an outperform vote while only 66.54% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMerusOutperform Votes36367.72% Underperform Votes17332.28% Avadel PharmaceuticalsOutperform Votes35066.54% Underperform Votes17633.46% Do analysts rate MRUS or AVDL? Merus presently has a consensus price target of $85.31, indicating a potential upside of 103.55%. Avadel Pharmaceuticals has a consensus price target of $19.88, indicating a potential upside of 143.87%. Given Avadel Pharmaceuticals' higher possible upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.13Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, MRUS or AVDL? Merus has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. SummaryMerus beats Avadel Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Remove Ads Get Avadel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVDL vs. The Competition Export to ExcelMetricAvadel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$787.53M$6.27B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-10.326.6921.6917.68Price / Sales4.66222.71373.8892.91Price / CashN/A65.6738.1534.64Price / Book8.325.776.353.94Net Income-$160.28M$142.01M$3.20B$247.45M7 Day Performance14.31%5.79%3.94%3.17%1 Month Performance-7.81%-15.47%-10.35%-8.53%1 Year Performance-54.70%-10.99%10.24%0.31% Avadel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVDLAvadel Pharmaceuticals2.4596 of 5 stars$8.03-1.5%$19.88+147.5%-54.9%$775.93M$169.12M-10.1670Analyst RevisionNews CoverageGap DownMRUSMerus2.9564 of 5 stars$37.39-1.9%$85.31+128.2%+4.0%$2.58B$36.13M-9.4737ALVOAlvotech1.5444 of 5 stars$8.32-2.1%$18.00+116.3%-34.6%$2.51B$489.68M-4.501,026Analyst RevisionGap DownAPLSApellis Pharmaceuticals4.1263 of 5 stars$19.80-0.9%$45.59+130.2%-65.0%$2.49B$781.37M-9.75770Analyst RevisionPositive NewsSRRKScholar Rock3.8865 of 5 stars$26.04-3.2%$42.67+63.9%+112.6%$2.47B$33.19M-11.08140Positive NewsCRNXCrinetics Pharmaceuticals3.5961 of 5 stars$26.38-1.9%$73.00+176.7%-32.0%$2.45B$1.04M-7.07210IMVTImmunovant2.2129 of 5 stars$14.39-1.3%$41.00+184.9%-51.2%$2.44BN/A-5.49120Short Interest ↑Positive NewsACADACADIA Pharmaceuticals4.019 of 5 stars$14.61-5.0%$23.93+63.8%-14.7%$2.44B$957.80M18.73510VKTXViking Therapeutics4.2623 of 5 stars$21.28-5.9%$95.18+347.3%-65.3%$2.39BN/A-21.2820Upcoming EarningsAnalyst ForecastOptions VolumeNews CoverageGap DownXENEXenon Pharmaceuticals2.7559 of 5 stars$30.63+4.2%$57.38+87.3%-18.6%$2.34B$9.43M-10.86210Analyst DowngradeOptions VolumeAnalyst RevisionNews CoveragePositive NewsHigh Trading VolumeIBRXImmunityBio1.9412 of 5 stars$2.72-3.9%$12.19+348.1%-49.6%$2.32B$14.75M-2.96590Analyst ForecastNews CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies MRUS Competitors ALVO Competitors APLS Competitors SRRK Competitors CRNX Competitors IMVT Competitors ACAD Competitors VKTX Competitors XENE Competitors IBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVDL) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVDL Stock Free AVDL Stock Alerts